Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16
Investors attending the conference are encouraged to schedule a one-on-one meeting at the conference with Arrowhead's CEO Dr. Christopher Anzalone by contacting firstname.lastname@example.org, or Brandi Floberg at email@example.com or 212-481-2050.
The presentation will be webcast live and can be accessed by visiting the Company's website at www.arrowheadresearch.com. A replay of the presentation will be archived on the Arrowhead website for 90 days.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company. For more information please visit http://www.arrowheadresearch.com.